State Street Corp Alaunos Therapeutics, Inc. Transaction History

State Street Corp

$2.25 Trillion
Q2 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.04 - $0.13 $112 - $364	-2,800 Reduced 0.37%	755,026 $52,000
Q2 2023 Aug 14, 2023	SELL	$0.43 - $0.65 $10,405 - $15,729	-24,199 Reduced 3.09%	757,826 $386,000
Q4 2022 Feb 14, 2023	SELL	$0.5 - $261.0 $1.2 Million - $625 Million	-2,396,398 Reduced 75.4%	782,025 $508,000
Q3 2022 Nov 15, 2022	BUY	$1.04 - $322.5 $2.41 Million - $747 Million	2,315,397 Added 268.29%	3,178,423 $5.47 Million
Q2 2022 Aug 15, 2022	SELL	$0.41 - $1.24 $1.78 Million - $5.4 Million	-4,352,327 Reduced 83.45%	863,026 $1.07 Million
Q1 2022 May 16, 2022	SELL	$0.62 - $1.17 $5.02 Million - $9.48 Million	-8,103,381 Reduced 60.84%	5,215,353 $3.4 Million
Q4 2021 Feb 14, 2022	BUY	$1.09 - $1.89 $1.79 Million - $3.1 Million	1,642,702 Added 14.07%	13,318,734 $14.5 Million
Q3 2021 Nov 15, 2021	BUY	$1.44 - $2.73 $1.18 Million - $2.23 Million	816,300 Added 7.52%	11,676,032 $21.3 Million
Q2 2021 Aug 16, 2021	SELL	$2.63 - $3.67 $3.53 Million - $4.92 Million	-1,341,616 Reduced 11.0%	10,859,732 $28.7 Million
Q1 2021 May 17, 2021	BUY	$2.82 - $5.6 $9.69 Million - $19.2 Million	3,436,522 Added 39.21%	12,201,348 $43.9 Million
Q4 2020 Feb 16, 2021	SELL	$2.09 - $3.09 $1.4 Million - $2.08 Million	-671,807 Reduced 7.12%	8,764,826 $22.1 Million
Q3 2020 Nov 10, 2020	BUY	$2.39 - $3.43 $3.29 Million - $4.72 Million	1,377,139 Added 17.09%	9,436,633 $23.8 Million
Q2 2020 Aug 14, 2020	BUY	$2.2 - $3.71 $3.65 Million - $6.16 Million	1,661,109 Added 25.96%	8,059,494 $26.4 Million
Q1 2020 May 11, 2020	BUY	$1.9 - $4.98 $12.2 Million - $31.9 Million	6,398,385 New	6,398,385 $15.7 Million

Others Institutions Holding TCRT

# of Institutions

Shares Held

92.6K

Call Options Held

Put Options Held

View Full List

About Alaunos Therapeutics, Inc.

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $458M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

More about TCRT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account